Neuland Laboratories Limited (NSE:NEULANDLAB)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Manufacture and Sale of Active Pharmaceutical Ingredients and Allied Services	20.23B	14.77B	15.59B	11.91B	9.52B
Total	20.23B	14.77B	15.59B	11.91B	9.52B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	4.84B	4.76B	3.37B	3.21B	2.39B
Europe	6.75B	4.29B	4.63B	3.60B	2.68B
Usa and North America	7.13B	4.22B	6.01B	3.65B	-
Rest of The World	1.50B	1.50B	1.58B	1.45B	1.63B
North America	-	-	-	-	2.53B
Total	20.23B	14.77B	15.59B	11.91B	9.23B

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error